ClinicalTrials.gg
Status unknownNCT04433559FSIADUpdated Jun 16, 2020

Study of Pharmacological Treatment in Women With Female Sexual Interest/Arousal Disorder (FSIAD).

A Phase 3 interventional study of Tadalafil 1,5 mg oral tablets and Placebo oral tablets in Sexual Dysfunctions, Psychological, sponsored by Lidia Larrañaga. Status unknown. Open to female participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2020-06-16.

Sponsored by Lidia Larrañaga · Phase 3, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Jun 2020), so the status shown — last known as Not yet recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
Female
01

Study summary

This clinical trial is a prospective, randomized, double-blind Phase III study with two arms to determine the efficacy and safety of the use of an IPDE in women with FSIAD.

Patients who meet all inclusion criteria and do not meet any of the exclusion criteria will enter the study and receive active product or placebo for 14 weeks.

Patients will be assigned to each treatment group in a randomized and parallel manner. In addition, all volunteers participating in the study will receive medical advice during the study.

The study will have a duration of minimum of 18 weeks and will consist of 3 periods.

Read the detailed description

This clinical trial is a prospective, randomized, double-blind Phase III study with two arms to determine the efficacy and safety of the use of an IPDE in women with FSIAD.

Patients who meet all inclusion criteria and do not meet any of the exclusion criteria will enter the study and receive active product or placebo for 14 weeks.

Patients will be assigned to each treatment group in a randomized and parallel manner. In addition, all volunteers participating in the study will receive medical advice during the study.

The study will have a duration of minimum of 18 weeks and will consist of 3 periods

02

Conditions studied

  • Sexual Dysfunctions, Psychological
03

In context

Sexual Dysfunctions, Psychological

138 studies on the registry are indexed under Sexual Dysfunctions, Psychological; 10 are open to participants now.

This study's planned enrollment of 80 is below the median of 100 across 114 interventional studies indexed under Sexual Dysfunctions, Psychological.

Browse Sexual Dysfunctions, Psychological studies →

Lead sponsor

This is the only study on the registry with Lidia Larrañaga as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Women between 18 and 65 years old. Women of childbearing age (premenopausal, not surgically sterilized at least 3 months before the Selection Visit) must be used during the study a highly effective method such as:

    • contraceptive methods or partner vasectomy, and confirm who are not pregnant by pregnancy test negative in the Selection Consultation.

      1. Signature of the obtained in writing,including a data protection declaration before the participation in the study.
      1. Women with disorders of interest and sexual arousal diagnosed using a semi-structured questionnaire of 5 questions based on criteria.

Exclusion criteria

Exclusion Criteria :

  1. The following groups of patients with cardiovascular risk:

    • Patients who had suffered myocardial infarction in the 90s previous days,
    • Patients with unstable angina or angina produced during sexual activity,
    • Patients with heart failure corresponding to class II or higher than the classification (NYHA) in the previous 6 months,
    • Patients with uncontrolled arrhythmias,
    • Patients who had suffered a stroke in the previous 6 months.
  2. Patients with disorders of female sexual arousal of origin neurogenic.
  3. Patients with female sexual dysfunction associated with disorders psychiatric.
  4. Patients with a partner who suffers from sexual dysfunction.
  5. Patients with dysphoric excitation disorder and / or with sensation unpleasant genital thickening.
  6. Patients with a history of severe thromboembolic disease, hepatic, renal, or neoplastic.
  7. Uncontrolled diabetic patients (> 8% in the last control).
  8. Patients with depression and / or taking antidepressants.
  9. Lactation
  10. to tadalafil and / or drugs and products related (including of the formulation).
  11. Patients undergoing treatment with any form of organic nitrate.
  12. Patients on treatment with potent inhibitors (ritonavir, ketoconazole, itraconazole, clarithromycin, erythromycin, and saquinavir) and strong CYP3A4 inducers (carbamazepine, phenytoin, phenobarbital, St. John's wort, rifampin).
  13. Patients who have loss of vision in one eye a consequence of anterior ischemic optic neuropathy not arteritic.
  14. Patients with any pelvic surgery in the previous 6 months.
  15. Known history of drug and / or alcohol abuse in the 6 months prior to the selection consultation.
  16. Participation in another study in the 3 months prior to the consultation of selection.
  17. Any illness that, in the investigator's judgment, can interfere with compliance with study procedures or study evaluations.
  18. Patient with any medical or surgical condition that may interfere with absorption, distribution, metabolism or excretion of the study drug according to the criteria of the researcher.
  19. Patients in judicial or police custody.
  20. Patients with difficulties in understanding the language in which they gives the information to the subject.
  21. Patients who do not agree to the transmission of their anonymous data regarding the documentation and notification functions.
  22. Study center, sponsor or CRO staff, their own researcher or relatives of the same.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
80 participants (estimated)

Study arms

  • Active comparator
    Group Active Tadalafile

    One oral tablet of 1.5 mg IPDE daily for 14 weeks of treatment.

    Drug: Tadalafil 1,5 mg oral tablets

  • Placebo comparator
    Group Placebo

    One oral tablet of placebo daily for 14 weeks of treatment.

    Drug: Placebo oral tablets

Interventions

  • Use of tadalafil in the treatment of FSIAD

    Also known as: Tadalafil

  • DrugPlacebo oral tablets

    Use of placebo in control group

    Also known as: Placebo

06

What researchers measure

Primary outcomes

  1. Effect of IPDE (Tadalafile) according to FSFI (Female Sexual Function Index)

    To determine the effect of IPDE at a dose of 1.5 mg versus placebo in women with disorders of interest and sexual arousal using the FSFI (Female Sexual Function Index). FSFI contains 19 questions, with each questions with a value minimum of 0 and maximum of 6 points, beeing 0 the worst scenario y 6 the best scenario.

    Time frame: 14 weeks

Secondary outcomes

  1. Comparative IPDE Vs placebo according to FSFI

    To compare the effect of IPDE with respect to placebo in women with disorders of interest and sexual arousal using the FSFI (Female Sexual Function Index). FSFI contains 19 questions, with each questions with a value minimum of 0 and maximum of 6 points, beeing 0 the worst scenario y 6 the best scenario.

    Time frame: 14 weeks

  2. Comparaive of IPDE Vs placebo according NSSS-Short (New Sexual Satisfaction Scale)

    To compare the effect of IPDE with respect to placebo in women with disorders of interest and sexual arousal using the questionnaire "The New Sexual Satisfaction Scale" (NSSS-Short). NSSS-Short (New Sexual Satisfaction Scale) contains 7 questions, with each questions with a value minimum of 0 and maximum of 100 points, beeing 0 the worst scenario y 100 the best scenario.

    Time frame: 14 weeks

  3. Comparative IPDE Vs placebo according to the TSQM (Treatment Satisfaction questionnaire for Medication)

    To compare the effect of IPDE with respect to placebo in women with disorders of interest and sexual arousal using the "Treatment Satisfaction questionnaire for Medication" (TSQM) version 1.4. TSQM (Treatment Satisfaction questionnaire for Medication) contains 14 questions with each questions with a value minimum of 0 and maximum of 80 points, beeing 0 the worst scenario y 80 the best scenario.

    Time frame: 14 weeks

  4. Comparative of IPDE Vs placebo according to number of sexual events

    To compare the effect of IPDE with respect to placebo in women with sexual interest and arousal disorder by measuring the number of sexual events recorded in the weekly diary. The diary will be fullfilled by the women according to the number of sexual events.

    Time frame: 14 weeks

  5. Comparative of IPDE Vs placebo according to the sexual satisfaction

    To compare the effect of IPDE with respect to placebo in women with sexual interest and arousal disorder by measuring the sexual satisfaction of sexual intercourse. The scale will contain 3 questions, with a visual analog scale. This visual analog scale will contain a scale with different visual easy identificable progesion faces, from very sad face to very happy face, beeging the first sad face, the no satisfaction point, and the last very happy face the very satisfactory sexual event point.

    Time frame: 14 weeks

  6. Comparative of IPDE Vs placebo according to ease of arousal

    To compare the effect of IPDE with respect to placebo in women with disorder of interest and sexual arousal by measuring the ease of arousal during sexual intercourse determined using an analog visual scale. The scale will contain 3 questions, with a visual analog scale. This visual analog scale will contain a scale with different visual easy identificable progesion faces, from very sad face to very happy face, beeging the first sad face, the no satisfaction point, and the last very happy face the very satisfactory sexual event point.

    Time frame: 14 weeks

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Aug 2020; primary completion for Aug 2021, 12 months later.

How these figures are worked out, and which studies are left out of them.

Registered
May 6, 2020
First posted
Jun 16, 2020
StartEst.
Aug 2020
Primary completionEst.
Aug 2021
CompletionEst.
Aug 2021
Last update
Jun 16, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 16, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04433559
Lead sponsor
Lidia Larrañaga
Responsible party
Lidia Larrañaga (Clinical Trial Coordinator, Laboratorios LITAPHAR, S.L.) — Sponsor-investigator
First posted
Jun 16, 2020
Start date
Aug 2020 (estimated)
Primary completion
Aug 2021 (estimated)
Completion
Aug 2021 (estimated)
Last update
Jun 16, 2020

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jun 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tadalafil

Start the discussion